Harmony Biosciences Holdings (HRMY)vsJohnson & Johnson (JNJ)
HRMY
Harmony Biosciences Holdings
$38.50
+1.45%
HEALTHCARE · Cap: $2.21B
JNJ
Johnson & Johnson
$275.19
+1.53%
HEALTHCARE · Cap: $615.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 10248% more annual revenue ($99.33B vs $959.90M). HRMY leads profitability with a 18.9% profit margin vs 16.2%. HRMY trades at a lower P/E of 12.2x. HRMY earns a higher WallStSmart Score of 75/100 (B).
HRMY
Strong Buy75
out of 100
Grade: B
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HRMY.
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$275.19
$131.07 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 34.2%
Revenue surging 30.3% year-over-year
Earnings expanding 88.2% YoY
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Areas to Watch
Weak financial health signals
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : HRMY
The strongest argument for HRMY centers on Operating Margin, Revenue Growth, EPS Growth. Profitability is solid with margins at 18.9% and operating margin at 34.2%. Revenue growth of 30.3% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bear Case : HRMY
The primary concerns for HRMY are Piotroski F-Score.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
HRMY profiles as a growth stock while JNJ is a mature play — different risk/reward profiles.
HRMY carries more volatility with a beta of 1.01 — expect wider price swings.
HRMY is growing revenue faster at 30.3% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
HRMY scores higher overall (75/100 vs 57/100), backed by strong 18.9% margins and 30.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Harmony Biosciences Holdings
HEALTHCARE · BIOTECHNOLOGY · USA
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?